LEXICON PHARMACEUTICALS, INC. Total Assets
LEXICON PHARMACEUTICALS, INC. (LXRX) had Total Assets of $250.06 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-08-06
- 2026-06-30: Assets $250.06M.
- 2026-03-31: Assets $268.82M.
- 2025-12-31: Assets $184.99M.
- 2025-09-30: Assets $205.93M.
| Period end | Assets | Assets as first filed |
|---|---|---|
| 2026-06-30 | $250.06M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $268.82M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $184.99M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $205.93M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $225.58M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $297.67M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $298.42M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $321.12M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $373.36M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $417.22M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $229.43M 10-K · filed 2025-03-07 | |
| 2023-09-30 | $276.48M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $316.72M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $162.72M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $194.30M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $191.69M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $112.33M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $136.18M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $136.91M 10-K · filed 2023-03-03 | |
| 2021-09-30 | $172.33M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $171.67M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $193.26M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $203.79M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $178.93M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $322.54M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $370.57M 10-Q · filed 2020-04-27 | |
| 2019-12-31 | $417.71M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $444.59M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $233.14M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $258.52M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $284.14M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $310.19M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $332.94M 10-Q · filed 2018-07-30 | |
| 2018-03-31 | $386.81M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $436.54M 10-K · filed 2019-03-15 | |
| 2017-09-30 | $329.49M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $363.51M 10-Q · filed 2017-08-01 | |
| 2017-03-31 | $396.26M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $475.63M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $516.95M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $558.13M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $611.34M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $651.96M 10-K · filed 2017-03-06 | $654.83M 10-K · filed 2016-03-11 |
| 2015-09-30 | $391.14M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $415.96M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $444.68M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $471.38M 10-K · filed 2016-03-11 | |
| 2014-09-30 | $187.52M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $224.06M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $243.60M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $274.16M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $299.46M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $323.39M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $347.27M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $371.78M 10-K · filed 2014-03-07 | |
| 2012-09-30 | $357.83M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $381.06M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $402.79M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $430.51M 10-K · filed 2013-03-11 | |
| 2011-09-30 | $294.71M 10-Q · filed 2011-11-01 | |
| 2011-06-30 | $315.92M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $366.88M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |